<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714411</url>
  </required_header>
  <id_info>
    <org_study_id>014.PHA.2020.A</org_study_id>
    <nct_id>NCT04714411</nct_id>
  </id_info>
  <brief_title>Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections</brief_title>
  <official_title>Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, open-label, two-center study to assess the safety of omadacycline&#xD;
      use in the treatment of hospitalized subjects with moderate to severe DFI who are at a high&#xD;
      risk for development of CDI, AKI, and/or resistant pathogens compared to retrospective&#xD;
      controls. Prospective enrollment will be continued until the sample size is achieved up to&#xD;
      one year form start date (anticipate August 2020 - August 2021).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a year-long study with planned enrollment of 57 patients (in addition to 114&#xD;
      historical control patients) evaluating the use of omadacycline for treatment of diabetic&#xD;
      foot infections (DFI). Omadacycline (NuzyraÂ®) is a FDA approved antibiotic for skin and skin&#xD;
      structure infection and community-acquired pneumonia. This study is considered to be&#xD;
      investigational because data is being collected on the use of Omadacycline for the treatment&#xD;
      of DFI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AKI based on RIFLE criteria</measure>
    <time_frame>Sept 2020 - Aug 2021</time_frame>
    <description>Risk, injury, failure, loss and ESRD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clostridioides difficile Infection</measure>
    <time_frame>Sept 2020 - Aug 2021</time_frame>
    <description>Frequency of Clostridioides difficile Infections while taking Omadacycline compared to other antibiotics</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Foot Infection</condition>
  <arm_group>
    <arm_group_label>Retrospective Cohort</arm_group_label>
    <description>A historical matched case cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Cohort</arm_group_label>
    <description>Subjects will be screened daily via review of the EMR reports of inpatient admissions. Those receiving antibiotics with a notated source of skin/soft tissue infection will be further reviewed to determine if the source of infection is a DFI without suspected or confirmed osteomyelitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omadacycline</intervention_name>
    <description>Omadacycline monotgherapy</description>
    <arm_group_label>Prospective Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult diabetic with DFI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects will be eligible for inclusion if hospitalized, 18 years or&#xD;
             older, diagnosed with type 1 or 2 diabetes, and have DFI with the additional clinical&#xD;
             criteria as specified below:&#xD;
&#xD;
               -  Acute infection or worsening without systemic antimicrobials within the previous&#xD;
                  14 days&#xD;
&#xD;
               -  At least one full or partial thickness-infected ulcer at or below the ankle AND&#xD;
&#xD;
               -  Purulent drainage OR&#xD;
&#xD;
               -  Two of the following:&#xD;
&#xD;
                    -  Erythema&#xD;
&#xD;
                    -  Local edema&#xD;
&#xD;
                    -  Fluctuance&#xD;
&#xD;
                    -  Induration&#xD;
&#xD;
                    -  Increased local warmth&#xD;
&#xD;
                    -  Fever&#xD;
&#xD;
               -  No systemic antimicrobials with current hospital admission for more than 48 hours&#xD;
                  prior to enrollment&#xD;
&#xD;
          -  Not currently enrolled in any other clinical trial&#xD;
&#xD;
          -  Provides informed consent&#xD;
&#xD;
          -  Likely to be compliant with all study-related procedures and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Confirmed or high suspicion of osteomyelitis at the time of enrollment, as evidenced&#xD;
             by:&#xD;
&#xD;
               -  Imaging (X-ray or MRI); imaging will be completed in order to rule out&#xD;
                  osteomyelitis in subjects with any of the following conditions:&#xD;
&#xD;
                    -  Soft tissue sinus tract&#xD;
&#xD;
                    -  Red, swollen (sausage) toe and ulcer&#xD;
&#xD;
                    -  Deep ulcer&#xD;
&#xD;
                    -  Ulcer over a bony prominence&#xD;
&#xD;
               -  Pathology (bone biopsy/culture)&#xD;
&#xD;
               -  Visible exposed bone&#xD;
&#xD;
               -  Positive probe-to-bone test (negative predictive value of 98 percent) 25&#xD;
&#xD;
          -  Has any gangrenous ulcers or necrotizing fasciitis&#xD;
&#xD;
          -  Has a pathogen known to be resistant to omadacycline&#xD;
&#xD;
          -  Administration of additional systemic antibiotics in combination with omadacycline,&#xD;
             not including topical routes or oral vancomycin/fidaxomicin given their local activity&#xD;
             within the GI tract&#xD;
&#xD;
          -  Contraindication or hypersensitivity to omadacycline/tetracyclines&#xD;
&#xD;
          -  Unwilling or unable to participate in study-related procedures or visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Crotty, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystee Cooper, DHEd</last_name>
    <phone>214-947-1280</phone>
    <email>ClinicalResearch@mhd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy Chan, Ph.D.</last_name>
    <phone>214-947-1280</phone>
    <email>ClinicalResearch@mhd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Crotty, PharmD</last_name>
      <phone>214-941-2400</phone>
      <email>matthewcrotty@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Crotty, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Charlton Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Crotty, PharmD</last_name>
      <email>matthewcrotty@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Crotty, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Focal Infection</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

